These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7333068)

  • 1. [Effect of the administration of silymarin on serum lipid levels].
    Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
    Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S; La Spina E; Fichera C; Cultrera E; Patanè M; Ciulla P
    Arch Sci Med (Torino); 1982; 139(4):441-8. PubMed ID: 7168636
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of procetofen on lipoproteins and blood lipids in patients with hyperlipemia].
    Abaurre R; Vega J; Maneschi E; Bernabe H
    Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 7219169
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P; Bittolo-Bon G; Alessandrini P
    Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
    [No Abstract]   [Full Text] [Related]  

  • 6. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of silymarin on serum lipoproteins in hyperlipemic rats].
    Mai K
    Zhonghua Xin Xue Guan Bing Za Zhi; 1987 Feb; 15(1):49-51. PubMed ID: 3608787
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial.
    Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A
    Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129
    [No Abstract]   [Full Text] [Related]  

  • 13. [Silymarin treatment of alcoholic liver disease].
    Orv Hetil; 1990 Jul; 131(29):1607-9. PubMed ID: 2392321
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
    Graisely B; Cloarec M
    Sem Hop; 1980 Jun 18-25; 56(25-28):1221-5. PubMed ID: 6256875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of lipanthyl therapy on hyperlipoproteinemia type II/a, II/b and IV].
    Karádi I; Pados G; Németh-Csóka M; Romics L
    Orv Hetil; 1988 Aug; 129(33):1757-60. PubMed ID: 3174116
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
    Hernández C; Lecube A; Barberá G; Chacón P; Lima J; Simó R
    Med Sci Monit; 2003 Mar; 9(3):CR114-9. PubMed ID: 12640339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of polyenylphosphatidylcholine (PPC) on serum lipids in patients with hyperlipoproteinemia. A double-blind study].
    Horsch AK; Majolk I; Heuck CC; Göpfert E
    Vasa; 1986; 15(3):251-5. PubMed ID: 3532609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.